产品
编 号：F749371
分子式：C51H77N13O9
分子量：1016.24
分子式：C51H77N13O9
分子量：1016.24
产品类型
规格
价格
是否有货
5mg
询价
询价
10mg
询价
询价
结构图
CAS No: 2147724-76-1
产品详情
生物活性：
P8RI (D-P8RI) is a biomimetic peptide of CD31 and a CD31 agonist. P8RI binds to the juxtamembrane amino acid sequence of the ectodomain of CD31, shows an immunosuppressive effect through restoration of the CD31 inhibitory pathway.
体内研究：
P8RI (2.5 mg/kg；皮下注射；ADIM 发生后 7 至 28 天) 通过促进壁内血肿的消退和体内解剖主动脉中胶原蛋白的产生来防止动脉瘤转化，与该部位 M2 巨噬细胞的富集有关。Animal Model:Apo E -/- mice (male, 28-week-old) implanted with Ang II-releasing pumps (a model of experimental acute aortic dissection and intramural hematoma (ADIM))
Dosage:2.5 mg/kg
Administration:Subcutaneous injection; daily from 7 to 28 (after the implantation of the osmotic pump delivering Ang II)
Result:Aneurysmal transformation was significantly reduced.
体外研究：
P8RI (D- P8RI) 被设计为具有全 D 型氨基酸的逆反肽，可保持生物活性并赋予血浆蛋白酶抗性。
P8RI (D-P8RI) is a biomimetic peptide of CD31 and a CD31 agonist. P8RI binds to the juxtamembrane amino acid sequence of the ectodomain of CD31, shows an immunosuppressive effect through restoration of the CD31 inhibitory pathway.
体内研究：
P8RI (2.5 mg/kg；皮下注射；ADIM 发生后 7 至 28 天) 通过促进壁内血肿的消退和体内解剖主动脉中胶原蛋白的产生来防止动脉瘤转化，与该部位 M2 巨噬细胞的富集有关。Animal Model:Apo E -/- mice (male, 28-week-old) implanted with Ang II-releasing pumps (a model of experimental acute aortic dissection and intramural hematoma (ADIM))
Dosage:2.5 mg/kg
Administration:Subcutaneous injection; daily from 7 to 28 (after the implantation of the osmotic pump delivering Ang II)
Result:Aneurysmal transformation was significantly reduced.
体外研究：
P8RI (D- P8RI) 被设计为具有全 D 型氨基酸的逆反肽，可保持生物活性并赋予血浆蛋白酶抗性。
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备